Skip to main content

Transplantation unit (Hematology)

There are two types of hematopoietic stem cell transplantation:

  • autotransplantation: autologous transplantation, using stem cells taken from the patient,
  • allotransplantation: allogenic transplantation,  using stem cells taken from a compatible brother or sister (known as a family or related transplant), or the stem cells of a voluntary and anonymous donor (an unrelated allogenic transplant). 

In practice, a transplant that follows a course of chemotherapy (the conditioning) takes place like a blood transfusion, the stem cells themselves lodging in the bone cavities where they multiply and ensure the restoral of the hematological and immune system. 

The first autologous transplantation of stem cells at the Jules Bordet Institute was carried out in 1981, followed by the first allogenic transplantation in 1984. 

Our programme was approved in 2009 by the Joint Accreditation Committee of the ISCT and EBMT or JACIE, recognising it as a centre of excellence for autologous and related and unrelated allogenic stem cell transplantations. 

The programme is growing, given the clear increase in transplant indications. We currently carry out about 35 autotransplants and 35 allotransplants a year. For the allotransplants we have a sterile unit with  6 laminar flow chambers.

Our programme is well supported by several specialists in medicine in addition to the hematologists specialising in transplantations, including infectiologists, intensivists and other specialists who possess the necessary skills to treat our patients. 

Also, in order to provide our patients with the most innovative treatment, the unit is engaged in clinical research
• Academic, in cooperation with the Belgian Hematological Society (BHS),  the EORTC, the LYSA, the IFM and the EBMT
• In cooperation with biotechnology firms for the handling of the graft in the framework of immunomodulation. 

Research projects


 

Project 1

A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with posttransplant cyclophosphamide in patients with a hematologic malignancy

Our team

Head of Department
- Prof Nathalie Meuleman -  Hematologist (Multiple Melomas and Plasmocytary Disorders: Autotransplants)

Head of Transplantation Unit
Prof Philippe Lewalle - Hematologist (Allotransplants)

Heads of the Clinics
- Prof Sebastian Wittnebel - Hematologist (Leukemias, Myelodysplasias and Allotransplants)

- Prof Marie Maerevoet -   Hematologist (Lymphomas and Lymphoproliferative Disorders: Autotransplant

Professor Emeritus
Prof Dominique Bron – Hematologist (Lymphomas and Chronic Lymphoid Leukemias)

Resident doctors 
Dr Chloé Spilleboudt (Allotransplants)
Dr Marie Vercruysen (Autotransplants)
Dr Adriano Salaroli (Allogreffe)

Qualitician
Aurélie Timmermans
Olivier Carabin

Head Nurse
Patrick Crombez

Transplant coordination and health education nurse
Jaivenois Marie France

Transplant coordinator
Sandra Michiels

19/02/2020

 Scientific publications

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.

Authors : Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J
Year : 2020
Journal : Leukemia
Volume : 34
Pages : 224-233

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.

Authors : Thieblemont C, Howlett S, Casasnovas RO, Mounier N, Perrot A, Morschhauser F, Fruchart C, Daguindau N, Van Eygen K, Obéric L, Bouabdallah R, Pica GM, Nicolas-Virezelier E, Abraham J, Fitoussi O, Snauwaert S, Eisenmann JC, Lionne-Huyghe P, Bron D, Tricot S, Deeren D, Gonzalez H, Costello R, Le Du K, da Silva MG, Grosicki S, Trotman J, Catalano J, Caballero D, Greil R, Cohen AM, Gaulard P, Roulin L, Takeshita K, Casadebaig ML, Tilly H, Coiffier B
Year : 2020
Journal : Br J Haematol
Volume : 189
Pages : 84-96

Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer.

Authors : Sonnenblick A, Salmon-Divon M, Salgado R, Dvash E, Pondé N, Zahavi T, Salmon A, Loibl S, Denkert C, Joensuu H, Ameye L, Van den Eynden G, Kellokumpu-Lehtinen PL, Azaria A, Loi S, Michiels S, Richard F, Sotiriou C
Year : 2020
Journal : Int J Cancer

Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy.

Authors : Craciun L, de Wind R, Demetter P, Lucidi V, Bohlok A, Michiels S, Bouazza F, Vouche M, Tancredi I, Verset G, Garaud S, Naveaux C, Galdon MG, Gallo KW, Hendlisz A, Derijckere ID, Flamen P, Larsimont D, Donckier V
Year : 2020
Journal : BMC Cancer
Volume : 20
Pages : 135

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.

Authors : Roex G, Feys T, Beguin Y, Kerre T, Poiré X, Lewalle P, Vandenberghe P, Bron D, Anguille S
Year : 2020
Journal : Pharmaceutics
Volume : 12